Development of neuroleptic malignant syndrome after addition of sertraline to the treatment: A case report;Nöroleptik malign sendrom: Tedaviye sertralin eklenmesi sonrasi ortaya çikan bir olgunun sunumu

Klinik Psikofarmakoloji Bulteni

Volumn 17, Issue 1, 2007, Pages 30-33

  Orhan, F Özlem ^a,c   Zencirci, Beyazit ^b   Öksüz, Hafize ^b   Bayir, Ali ^a   Karaaslan, M Fatih ^a  

^a KSÜ Tip Fakültesi Psikiyatri AD   (Turkey)

^b Anesteziyoloji ve Reanimasyon AD ^*  (Turkey)

^c KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

Neuroleptic malignant syndrome; Polypharmacy; Sertraline

Indexed keywords

CHLORPROMAZINE; LITHIUM; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG MECHANISM; FEMALE; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PATHOGENESIS;

EID: 34047225187     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Védie C, Poinso F, Hemmi F, Rivet B. Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports. Eur Psychiatry 2000; 15: 334-337
2. Fekadu A, Bisson JI. Neuroleptic malignant syndrome: Diagnostic and therapeutic dilemmas. Behav Neurol 2005;16: 9-13
3. Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003; 107: 45-49
4. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49: 1163-1172
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202
6. Ananth J, Aduri K, Parameswaran S, Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica 2004; 16: 219-228
7. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156: 169-180
8. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report. Psychiatry Clin Neurosci 2005; 59: 504-507
9. M Yumru, HA Savaş, E Savaş. Tek Doz Klorpromazin Uygulamasi Sonrasi Gelişen ve Elektrokonvulsif Tedaviye Olumlu Yanit Veren Nöroleptik Malign Sendrom: Olgu Sunumu. Türkiye'de Psikiyatri 2005; 7:126-128
10. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33: 650-659
11. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003; 169: 439-442
12. Saka MC, Can S, Özgüven HD, Atbaşoǧlu EC. Antipsikotik İlaçlarin Yan Etkileri. Türkiye Klinikleri Dahili Tip Bilimleri Dergisi Psikiyatri 2005; 1:58-66
13. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990; 15: 518-521
14. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997; 31: 1481-1489
15. Assion H, Heinemann F, Laux G. Antidepressants and neuroleptic malignant syndrome. Eur Neuropsychopharmacology 1995; 5: 293
16. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004; 65: 1064-1068
17. A Yildiz, AS Gönül, L Tamam. Antidepresanlarin etki mekanizmalari. Klinik Psikofarmakoloji Bülteni 2002; 12:194-200
18. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998; 44: 378-381
19. Gonner F, Baumgartner R, Schupbach D, Merlo MC. Neuroleptic malignant syndrome during low dosed neuroleptic medication in first-episode psychosis: a case report. Psychopharmacology 1999; 144: 416-8.
20. Herken H , Kaya N, Aşkin R, Kucur R. Nöroleptik Malign Sendrom: 5 Olgu. Klinik Psikiyatri Dergisi 1998; 1:120-124
21. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18:317-325
22. Yüksel N. Psikofarmakoloji. 2.Baski, Ankara: Çizgi Tip Yayinevi, 2003:682
23. Heinemann F, Assion HJ, Hermes G, Ehrlich M. Paroxetine-induced neuroleptic malignant syndrome. Nervenarzt, 1997; 68: 664-666
24. Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA, Katritsis DE, Christodoulou GN. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. J Clin Psychopharmacol 2003; 23: 671-672
25. Shad MU, Preskorn SH. Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18: 346-347
26. Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005;162: 812
27. Assion HJ, Heinemann F, Laux G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 1998; 248: 231-239
28. Lopez Gaston OD, Wierzbinsky S, Lopez Gaston RS, Resnik S, Pardomenico S, Jorge M. Sertraline. Adverse effects due to the superposition of serotonic and malignant neuroleptic syndromes. Medicina (B Aires) 2000; 60: 241-244
29. Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004; 26: 386-390